Obesity Clinical Trial
Official title:
The Investigation of the Effects of Functional Inspiratory Muscle Training in Obese Individuals
NCT number | NCT06280183 |
Other study ID # | 323132 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | February 28, 2024 |
Est. completion date | June 30, 2025 |
In obese individuals, increased adipose tissue and systemic inflammation play a key role in the development of cardiometabolic diseases, pulmonary system dysfunction, and many respiratory diseases. Existing research has demonstrated beneficial clinical outcomes of inspiratory muscle training or combined aerobic and resistance exercise training in obese individuals. However, this focused on the isolated effects of exercise on obesity. In the current literature, no study is evaluating the effectiveness of functional inspiratory muscle training in obese individuals. This study aims to investigate the effects of functional inspiratory muscle training on body composition, cardiometabolic markers, functional capacity, respiratory function, respiratory muscle strength, and respiratory muscle performance in obese individuals.
Status | Recruiting |
Enrollment | 45 |
Est. completion date | June 30, 2025 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 25 Years to 60 Years |
Eligibility | Inclusion Criteria: - Those between the ages of 25-60 - According to the World Health Organization (WHO) classification, those with a body mass index between 30-40 kg/m2 - Volunteering to participate in the research Exclusion Criteria: - According to the World Health Organization (WHO) classification, body mass index is over 40 kg/m2 - Functional class III or IV according to the New York Heart Association (NYHA) classification - Those with a Charlson comorbidity score of 3 and above - Uncontrolled hypertension, diabetes and unstable angina pectoris - Cooperative disorders, orthopedic and neurological problems that may interfere with evaluation and treatment - Individuals with a history of lower extremity-related injury or surgery in the last six months - Being diagnosed with diabetes and having complications such as nephropathy, retinopathy and neuropathy - Those with accompanying chronic respiratory disease - Those with acute infection - Individuals with middle ear-related pathologies (such as tympanic membrane rupture, otitis) - Those with a STOP-Bang score of 3 and above - Individuals with a history of spontaneous or trauma-related pneumothorax - Smokers - Pregnancy |
Country | Name | City | State |
---|---|---|---|
Turkey | Biruni University | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Biruni University | Istanbul Galata University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Respiratory Muscle Strength | Respiratory muscle strength; It will be evaluated with an intraoral pressure measuring device in a sitting position. | 10 weeks | |
Primary | Incremental load test (Respiratory Muscle Endurance) | Respiratory muscle endurance will be evaluated by incremental load test. The incremental load test will be performed using the electronic inspiratory loading device (PowerBreathe®-KHP2). | 10 weeks | |
Primary | Forced expiratory volume 1st second (Respiratory Function) | Spirometric assessment will be performed to determine participants' forced expiratory volume in one second (FEV1). | 10 weeks | |
Primary | Forced vital capacity (Respiratory Function) | Spirometric assessment will be performed to determine participants' forced vital capacity (FVC). | 10 weeks. | |
Secondary | Comorbidity Assessment | "Charlson Comorbidity Index" (CMI) will be used to determine the comorbidity levels of obese individuals. The index, which consists of nineteen comorbid diagnosis groups, is a valid method for evaluating chronic diseases and measuring their relationship with mortality. All CMI scores are scored between 0-37. According to the results, 3 levels of comorbidity are defined: low (0), medium (1-2) and high (3+). | Day 1 | |
Secondary | Physical Activity Assessment | Step Count Measurement: Daily step count will be monitored to determine the physical activity level of the participants. Step count will be assessed with a wearable activity monitor, a portable, easy-to-use tool that can measure objectively (Huawei Watch Fit Special Edition). With its six-axis sensor, the device records the user's physical activity style information in its temporary memory throughout the duration of use. Participants will be asked to wear the activity monitor on their left wrist throughout and only remove it during bathing. After one week of use, the data recorded with the wearable activity monitor will be taken. | 10 weeks | |
Secondary | Edmonton Obesity Staging System (EOSS) | The Edmonton Obesity Staging System (EOSS) is a five-stage obesity classification system used to determine prognosis and guide treatment when assessing obesity-related risk. | Day 1 | |
Secondary | Functional Capacity | Submaximal functional exercise capacity of the participants will be evaluated with the six-minute walk test. | 10 weeks | |
Secondary | Peripheral Muscle Strength | M. Quadriceps muscle strength and hand grip strength measurement will be used to evaluate peripheral muscle strength. Hand-held dynamometer will be used to evaluate quadriceps muscle strength and hand grip strength. | 10 weeks | |
Secondary | Waist circumference | Waist circumference will be measured at belly level with the patient in an upright position during expiration, with both feet bearing equal weight. | 10 weeks | |
Secondary | Hip circumference | Hip circumference will be measured at the level of the greater femoral trochanter, with the patient in an upright position, with both feet bearing equal weight. | 10 weeks | |
Secondary | Body fat-muscle ratios | These measurements will be determined by bioelectrical impedance. | 10 weeks | |
Secondary | Glucose profile | Glucose profile after 12 hours of fasting will be measured | 10 weeks | |
Secondary | Lipid profile | Lipid profile after 12 hours of fasting will be measured | 10 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |